Lb Pharmaceuticals LBRX Institutional Ownership

Updated Oct 10, 2026

Lb Pharmaceuticals Inc (NASDAQ:LBRX) was held by 115 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Their combined stake equaled 98.74% of outstanding shares in Q2 2026, up from 98.38% in Q1 2026.
• Total shares held in Lb Pharmaceuticals rose 5.49% from Q1 2026.
• Of the 115 holders, 83 added to their positions, 14 reduced their stakes and 18 left their positions unchanged in Q2 2026.
• Combined, institutional investors held 29.76Mn shares of LBRX as of Q2 2026, up 1.55Mn from the prior quarter.
• Deep Track Capital, LP led 13F holders of LBRX with 3.35Mn shares as of June 30, 2026, or 11.12% of shares outstanding.
• The largest position increases in LBRX for Q2 2026 were by BlackRock, Inc. (+263.46K shares), Goldman Sachs Group Inc (+212.66K shares), Trails Edge Capital Partners, LP (+203.66K shares), Millennium Management LLC (+122.25K shares) and Ameriprise Financial Inc (+119.18K shares).
• Holders that trimmed the most shares of Lb Pharmaceuticals in Q2 2026 while keeping a position were TCG Crossover Management, LLC (-392.18K shares), Logos Global Management LP (-330K shares), Citadel Advisors LLC (-200.94K shares), UBS Group AG (-51.98K shares) and Russell Investments Group, Ltd. (-37.99K shares).
• Per Business Quant, the top 10 investors in LBRX for the quarter ended June 30, 2026 were Deep Track Capital, LP (3.35Mn shares), BlackRock, Inc. (2.73Mn shares), Ra Capital Management, L.P. (2.21Mn shares), Trails Edge Capital Partners, LP (1.52Mn shares), Commodore Capital LP (1.5Mn shares), JPMorgan Chase & Co (1.5Mn shares), TCG Crossover Management, LLC (1.45Mn shares), Caligan Partners LP (1.44Mn shares), Spruce Street Capital LP (1.38Mn shares) and Nantahala Capital Management, LLC (1.05Mn shares).